| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 173 | 2022 | 1109 | 20.900 |
Why?
|
| Naltrexone | 46 | 2021 | 195 | 8.730 |
Why?
|
| Alcohol Drinking | 76 | 2021 | 805 | 8.690 |
Why?
|
| Narcotic Antagonists | 38 | 2021 | 184 | 6.840 |
Why?
|
| Transferrin | 36 | 2020 | 94 | 5.520 |
Why?
|
| gamma-Aminobutyric Acid | 11 | 2021 | 208 | 3.740 |
Why?
|
| Alcohol Deterrents | 19 | 2021 | 86 | 3.380 |
Why?
|
| Receptors, Opioid, mu | 13 | 2021 | 70 | 3.210 |
Why?
|
| Glutamic Acid | 7 | 2021 | 332 | 2.870 |
Why?
|
| Substance Withdrawal Syndrome | 20 | 2021 | 435 | 2.400 |
Why?
|
| Gyrus Cinguli | 8 | 2021 | 113 | 2.390 |
Why?
|
| Ethanol | 34 | 2022 | 892 | 2.310 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 7 | 2021 | 82 | 2.210 |
Why?
|
| World Health Organization | 10 | 2021 | 53 | 2.200 |
Why?
|
| Adult | 157 | 2021 | 21375 | 2.170 |
Why?
|
| Catechol O-Methyltransferase | 4 | 2022 | 31 | 2.080 |
Why?
|
| Humans | 261 | 2022 | 68525 | 1.980 |
Why?
|
| Plants, Medicinal | 19 | 2006 | 43 | 1.960 |
Why?
|
| Male | 179 | 2021 | 37281 | 1.880 |
Why?
|
| Female | 174 | 2021 | 38015 | 1.830 |
Why?
|
| Polymorphism, Single Nucleotide | 24 | 2020 | 627 | 1.710 |
Why?
|
| Alcohol-Related Disorders | 8 | 2020 | 95 | 1.650 |
Why?
|
| Middle Aged | 116 | 2021 | 21119 | 1.640 |
Why?
|
| Alcohol Abstinence | 4 | 2020 | 23 | 1.630 |
Why?
|
| Biomarkers | 33 | 2018 | 1593 | 1.600 |
Why?
|
| Double-Blind Method | 37 | 2021 | 1737 | 1.580 |
Why?
|
| Aripiprazole | 6 | 2017 | 43 | 1.570 |
Why?
|
| Treatment Outcome | 54 | 2021 | 7028 | 1.530 |
Why?
|
| Antipsychotic Agents | 5 | 2017 | 247 | 1.440 |
Why?
|
| Substance-Related Disorders | 25 | 2021 | 1241 | 1.380 |
Why?
|
| Cyclohexanecarboxylic Acids | 6 | 2013 | 60 | 1.370 |
Why?
|
| Glutamine | 2 | 2019 | 45 | 1.370 |
Why?
|
| Amines | 6 | 2013 | 98 | 1.330 |
Why?
|
| Quinolones | 4 | 2010 | 60 | 1.330 |
Why?
|
| Taurine | 11 | 2021 | 51 | 1.310 |
Why?
|
| gamma-Glutamyltransferase | 12 | 2007 | 37 | 1.280 |
Why?
|
| Piperazines | 4 | 2010 | 206 | 1.240 |
Why?
|
| Brain | 17 | 2019 | 2175 | 1.140 |
Why?
|
| Frontal Lobe | 3 | 2019 | 156 | 1.090 |
Why?
|
| Quality of Life | 5 | 2021 | 1515 | 1.020 |
Why?
|
| Saponins | 8 | 2001 | 13 | 0.960 |
Why?
|
| Genotype | 26 | 2020 | 785 | 0.920 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2018 | 785 | 0.920 |
Why?
|
| Young Adult | 28 | 2021 | 5708 | 0.920 |
Why?
|
| Excitatory Amino Acid Antagonists | 4 | 2020 | 128 | 0.890 |
Why?
|
| Binge Drinking | 3 | 2021 | 50 | 0.890 |
Why?
|
| Clinical Trials as Topic | 12 | 2017 | 848 | 0.880 |
Why?
|
| Receptors, GABA-A | 5 | 2016 | 89 | 0.870 |
Why?
|
| Flumazenil | 3 | 2013 | 23 | 0.860 |
Why?
|
| Substance Abuse Detection | 3 | 2014 | 66 | 0.860 |
Why?
|
| Temperance | 12 | 2013 | 41 | 0.850 |
Why?
|
| Behavior Therapy | 6 | 2020 | 297 | 0.850 |
Why?
|
| Impulsive Behavior | 3 | 2017 | 85 | 0.790 |
Why?
|
| Aspartic Acid | 3 | 2019 | 65 | 0.790 |
Why?
|
| Cues | 14 | 2022 | 654 | 0.760 |
Why?
|
| Obsessive-Compulsive Disorder | 7 | 2001 | 88 | 0.760 |
Why?
|
| Blood Pressure | 5 | 2018 | 1447 | 0.750 |
Why?
|
| Trypanosoma cruzi | 3 | 2005 | 7 | 0.740 |
Why?
|
| Liver Cirrhosis, Alcoholic | 3 | 2016 | 14 | 0.730 |
Why?
|
| Dopamine Agonists | 4 | 2017 | 68 | 0.720 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 163 | 0.720 |
Why?
|
| Follow-Up Studies | 21 | 2019 | 3256 | 0.710 |
Why?
|
| Behavior, Addictive | 10 | 2012 | 317 | 0.700 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 4 | 2021 | 27 | 0.700 |
Why?
|
| Publishing | 1 | 2020 | 89 | 0.700 |
Why?
|
| Alleles | 7 | 2020 | 386 | 0.690 |
Why?
|
| Polymorphism, Genetic | 7 | 2018 | 301 | 0.680 |
Why?
|
| Alcoholic Intoxication | 5 | 2017 | 61 | 0.680 |
Why?
|
| Glycine | 1 | 2019 | 89 | 0.670 |
Why?
|
| Severity of Illness Index | 10 | 2017 | 1851 | 0.670 |
Why?
|
| Sialoglycoproteins | 3 | 2018 | 24 | 0.670 |
Why?
|
| Plant Extracts | 7 | 2006 | 122 | 0.660 |
Why?
|
| Motivation | 8 | 2017 | 561 | 0.660 |
Why?
|
| Plant Preparations | 5 | 2003 | 18 | 0.660 |
Why?
|
| Psychotherapy | 7 | 2011 | 253 | 0.650 |
Why?
|
| Mood Disorders | 3 | 2015 | 132 | 0.650 |
Why?
|
| Craving | 5 | 2019 | 200 | 0.640 |
Why?
|
| Chromatography, High Pressure Liquid | 9 | 2016 | 381 | 0.640 |
Why?
|
| Genetic Variation | 11 | 2012 | 220 | 0.630 |
Why?
|
| Psychiatric Status Rating Scales | 22 | 2013 | 782 | 0.630 |
Why?
|
| Depressive Disorder | 15 | 2021 | 621 | 0.620 |
Why?
|
| Bipolar Disorder | 4 | 2017 | 307 | 0.610 |
Why?
|
| Self-Control | 1 | 2017 | 9 | 0.610 |
Why?
|
| Toxins, Biological | 4 | 2000 | 23 | 0.600 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 1997 | 88 | 0.600 |
Why?
|
| Triterpenes | 5 | 2001 | 40 | 0.600 |
Why?
|
| Pharmacogenetics | 3 | 2021 | 47 | 0.590 |
Why?
|
| Plasmodium falciparum | 4 | 2006 | 45 | 0.590 |
Why?
|
| Glucuronates | 2 | 2014 | 19 | 0.590 |
Why?
|
| Plant Proteins | 4 | 2000 | 48 | 0.590 |
Why?
|
| Liver Function Tests | 8 | 2018 | 114 | 0.590 |
Why?
|
| Drug Therapy | 3 | 2005 | 71 | 0.580 |
Why?
|
| Nicotine | 2 | 2018 | 350 | 0.580 |
Why?
|
| Alkaloids | 6 | 1995 | 40 | 0.580 |
Why?
|
| Smoking | 5 | 2018 | 1449 | 0.570 |
Why?
|
| Combined Modality Therapy | 17 | 2013 | 951 | 0.560 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2020 | 929 | 0.560 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 2798 | 0.550 |
Why?
|
| Health Status | 1 | 2018 | 429 | 0.540 |
Why?
|
| Social Environment | 3 | 2012 | 182 | 0.540 |
Why?
|
| Genetic Markers | 7 | 2009 | 144 | 0.540 |
Why?
|
| Liver Cirrhosis | 2 | 2018 | 301 | 0.530 |
Why?
|
| Ambulatory Care | 8 | 2012 | 339 | 0.520 |
Why?
|
| Cognition | 3 | 2011 | 512 | 0.520 |
Why?
|
| Anticonvulsants | 4 | 2007 | 223 | 0.520 |
Why?
|
| Sulfuric Acid Esters | 1 | 2014 | 7 | 0.500 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2014 | 14 | 0.500 |
Why?
|
| Risk Factors | 19 | 2019 | 5719 | 0.470 |
Why?
|
| GABA Modulators | 3 | 2013 | 26 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2022 | 2222 | 0.460 |
Why?
|
| Antimalarials | 3 | 2004 | 71 | 0.450 |
Why?
|
| United States | 21 | 2021 | 7335 | 0.440 |
Why?
|
| Drug Therapy, Combination | 8 | 2013 | 648 | 0.440 |
Why?
|
| Fructose | 4 | 2014 | 51 | 0.440 |
Why?
|
| Anti-Anxiety Agents | 3 | 2002 | 107 | 0.430 |
Why?
|
| Liver Diseases, Alcoholic | 4 | 2018 | 27 | 0.420 |
Why?
|
| Anxiety Disorders | 6 | 2021 | 426 | 0.420 |
Why?
|
| Receptors, Nicotinic | 5 | 2011 | 41 | 0.420 |
Why?
|
| Hypertension | 4 | 2008 | 1531 | 0.420 |
Why?
|
| Goals | 2 | 2011 | 65 | 0.410 |
Why?
|
| Patient Compliance | 7 | 2008 | 402 | 0.410 |
Why?
|
| Carbamazepine | 4 | 2002 | 108 | 0.410 |
Why?
|
| Nerve Net | 1 | 2014 | 180 | 0.410 |
Why?
|
| Animals | 54 | 2014 | 20877 | 0.410 |
Why?
|
| Recurrence | 13 | 2020 | 948 | 0.400 |
Why?
|
| Brain Mapping | 7 | 2017 | 531 | 0.400 |
Why?
|
| Affect | 4 | 2014 | 218 | 0.400 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2010 | 5 | 0.390 |
Why?
|
| Substance Abuse Treatment Centers | 4 | 2007 | 71 | 0.390 |
Why?
|
| Prostaglandins E | 8 | 1991 | 54 | 0.390 |
Why?
|
| Adolescent | 22 | 2021 | 8903 | 0.380 |
Why?
|
| DNA Methylation | 3 | 2021 | 192 | 0.370 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2010 | 11 | 0.370 |
Why?
|
| Reward | 5 | 2017 | 201 | 0.370 |
Why?
|
| Analysis of Variance | 14 | 2008 | 1039 | 0.370 |
Why?
|
| Case-Control Studies | 12 | 2019 | 1548 | 0.360 |
Why?
|
| Carbohydrates | 3 | 2018 | 57 | 0.360 |
Why?
|
| Flavonoids | 6 | 2004 | 109 | 0.360 |
Why?
|
| Aged | 24 | 2021 | 14842 | 0.360 |
Why?
|
| Brain Chemistry | 2 | 2010 | 173 | 0.360 |
Why?
|
| Risk | 5 | 2021 | 563 | 0.350 |
Why?
|
| Mistletoe | 2 | 2000 | 2 | 0.340 |
Why?
|
| Self Report | 3 | 2019 | 370 | 0.340 |
Why?
|
| Lorazepam | 3 | 2009 | 54 | 0.340 |
Why?
|
| Corpus Striatum | 4 | 2018 | 278 | 0.340 |
Why?
|
| Models, Theoretical | 2 | 2010 | 384 | 0.340 |
Why?
|
| Amoxapine | 4 | 1993 | 7 | 0.330 |
Why?
|
| Single-Blind Method | 4 | 2018 | 249 | 0.330 |
Why?
|
| Antiprotozoal Agents | 2 | 2006 | 23 | 0.330 |
Why?
|
| DNA | 4 | 2013 | 597 | 0.330 |
Why?
|
| Longitudinal Studies | 5 | 2018 | 1054 | 0.330 |
Why?
|
| Social Behavior | 4 | 2004 | 164 | 0.320 |
Why?
|
| Dopamine | 3 | 2022 | 474 | 0.320 |
Why?
|
| Time Factors | 11 | 2019 | 4655 | 0.320 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 174 | 0.320 |
Why?
|
| Neurotransmitter Agents | 3 | 2004 | 102 | 0.320 |
Why?
|
| Reproducibility of Results | 12 | 2022 | 2077 | 0.320 |
Why?
|
| Biflavonoids | 2 | 2005 | 3 | 0.310 |
Why?
|
| Mental Health | 2 | 2020 | 278 | 0.310 |
Why?
|
| Minisatellite Repeats | 3 | 2017 | 16 | 0.310 |
Why?
|
| Central Nervous System Depressants | 5 | 2017 | 182 | 0.310 |
Why?
|
| Pharmacogenomic Variants | 2 | 2017 | 15 | 0.310 |
Why?
|
| Antisocial Personality Disorder | 3 | 2012 | 30 | 0.310 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 2016 | 346 | 0.300 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2011 | 51 | 0.300 |
Why?
|
| Lectins | 2 | 1997 | 81 | 0.300 |
Why?
|
| Depressive Disorder, Major | 5 | 2011 | 438 | 0.290 |
Why?
|
| Data Interpretation, Statistical | 6 | 2016 | 329 | 0.290 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2013 | 32 | 0.290 |
Why?
|
| Trypanosoma brucei rhodesiense | 2 | 2006 | 2 | 0.290 |
Why?
|
| Leishmania donovani | 2 | 2006 | 19 | 0.290 |
Why?
|
| Health Surveys | 2 | 2020 | 488 | 0.280 |
Why?
|
| Prefrontal Cortex | 5 | 2018 | 639 | 0.280 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 1465 | 0.280 |
Why?
|
| Stress Disorders, Post-Traumatic | 8 | 2011 | 1506 | 0.280 |
Why?
|
| Psychotropic Drugs | 3 | 2007 | 83 | 0.280 |
Why?
|
| Trypanocidal Agents | 2 | 2004 | 11 | 0.270 |
Why?
|
| Glycerophospholipids | 2 | 2016 | 20 | 0.270 |
Why?
|
| Blood Chemical Analysis | 2 | 2017 | 43 | 0.260 |
Why?
|
| Anacardiaceae | 1 | 2004 | 1 | 0.260 |
Why?
|
| Life Change Events | 3 | 2011 | 223 | 0.260 |
Why?
|
| Abnormalities, Drug-Induced | 7 | 1991 | 34 | 0.250 |
Why?
|
| Cocaine-Related Disorders | 6 | 2018 | 504 | 0.250 |
Why?
|
| Phytotherapy | 1 | 2004 | 53 | 0.250 |
Why?
|
| Medication Adherence | 4 | 2019 | 335 | 0.250 |
Why?
|
| Plants | 3 | 1995 | 26 | 0.250 |
Why?
|
| Genome-Wide Association Study | 6 | 2021 | 240 | 0.240 |
Why?
|
| Comorbidity | 11 | 2015 | 1425 | 0.240 |
Why?
|
| Physicians, Family | 1 | 2004 | 82 | 0.240 |
Why?
|
| Reference Standards | 7 | 2017 | 115 | 0.240 |
Why?
|
| Homozygote | 3 | 2016 | 119 | 0.240 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2017 | 109 | 0.240 |
Why?
|
| Valproic Acid | 3 | 2014 | 93 | 0.240 |
Why?
|
| Patient Selection | 4 | 2009 | 592 | 0.240 |
Why?
|
| Health Care Surveys | 1 | 2004 | 239 | 0.230 |
Why?
|
| Logistic Models | 7 | 2011 | 1419 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2008 | 772 | 0.230 |
Why?
|
| Prospective Studies | 8 | 2020 | 3702 | 0.230 |
Why?
|
| Cell Survival | 6 | 2006 | 901 | 0.230 |
Why?
|
| Tobacco Use Disorder | 4 | 2011 | 432 | 0.230 |
Why?
|
| Medicine, Traditional | 3 | 1988 | 7 | 0.220 |
Why?
|
| Sex Factors | 8 | 2018 | 1265 | 0.220 |
Why?
|
| Caprifoliaceae | 1 | 2002 | 1 | 0.220 |
Why?
|
| Mass Screening | 3 | 2006 | 837 | 0.220 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 2022 | 5 | 0.220 |
Why?
|
| Dibenzoxazepines | 3 | 1990 | 6 | 0.220 |
Why?
|
| Cocaine | 3 | 2017 | 555 | 0.220 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 8 | 2019 | 257 | 0.210 |
Why?
|
| Perphenazine | 2 | 1993 | 2 | 0.210 |
Why?
|
| Amitriptyline | 2 | 1993 | 11 | 0.210 |
Why?
|
| Ethnopharmacology | 1 | 2001 | 1 | 0.210 |
Why?
|
| Rubiaceae | 1 | 2001 | 3 | 0.210 |
Why?
|
| Leishmania | 1 | 2001 | 6 | 0.210 |
Why?
|
| Haplotypes | 7 | 2012 | 174 | 0.210 |
Why?
|
| Cartilage Oligomeric Matrix Protein | 1 | 2021 | 2 | 0.210 |
Why?
|
| Child Abuse | 4 | 2011 | 186 | 0.200 |
Why?
|
| Iridoids | 3 | 1990 | 4 | 0.200 |
Why?
|
| Magnoliopsida | 1 | 2001 | 5 | 0.200 |
Why?
|
| Balsaminaceae | 1 | 2001 | 1 | 0.200 |
Why?
|
| Prevalence | 5 | 2021 | 1609 | 0.200 |
Why?
|
| Pyrans | 3 | 1990 | 16 | 0.200 |
Why?
|
| Naphthoquinones | 1 | 2001 | 14 | 0.200 |
Why?
|
| Neuroimaging | 2 | 2014 | 122 | 0.200 |
Why?
|
| Linkage Disequilibrium | 6 | 2012 | 91 | 0.200 |
Why?
|
| Glycoproteins | 2 | 2000 | 238 | 0.200 |
Why?
|
| Checklist | 1 | 2022 | 76 | 0.200 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 334 | 0.200 |
Why?
|
| Nitrous Oxide | 1 | 2001 | 7 | 0.200 |
Why?
|
| Personality Inventory | 4 | 2011 | 196 | 0.200 |
Why?
|
| Adolescent Behavior | 2 | 2020 | 264 | 0.200 |
Why?
|
| Nitrites | 1 | 2001 | 53 | 0.190 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 2264 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 766 | 0.190 |
Why?
|
| Varenicline | 2 | 2019 | 98 | 0.190 |
Why?
|
| Personality Assessment | 4 | 1995 | 71 | 0.190 |
Why?
|
| Blood Alcohol Content | 1 | 2020 | 4 | 0.190 |
Why?
|
| Sertraline | 4 | 2005 | 62 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2002 | 94 | 0.190 |
Why?
|
| Gene Frequency | 9 | 2011 | 207 | 0.190 |
Why?
|
| Receptors, Dopamine D4 | 2 | 2017 | 10 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2009 | 1745 | 0.190 |
Why?
|
| Models, Psychological | 2 | 1999 | 180 | 0.190 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2001 | 45 | 0.190 |
Why?
|
| Solvents | 1 | 2001 | 108 | 0.190 |
Why?
|
| Pregnancy, Animal | 3 | 1990 | 27 | 0.180 |
Why?
|
| Molecular Structure | 7 | 2011 | 397 | 0.180 |
Why?
|
| United Kingdom | 1 | 2020 | 152 | 0.180 |
Why?
|
| Motivational Interviewing | 1 | 2020 | 40 | 0.180 |
Why?
|
| Alcohol Withdrawal Delirium | 4 | 1996 | 24 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 467 | 0.180 |
Why?
|
| Mesalamine | 1 | 2019 | 6 | 0.170 |
Why?
|
| Electronic Prescribing | 1 | 2019 | 9 | 0.170 |
Why?
|
| Drug Interactions | 3 | 2018 | 289 | 0.170 |
Why?
|
| Rats | 16 | 2011 | 5300 | 0.170 |
Why?
|
| Serotonin Antagonists | 3 | 2008 | 31 | 0.170 |
Why?
|
| Kindling, Neurologic | 3 | 2000 | 24 | 0.170 |
Why?
|
| Clinical Enzyme Tests | 1 | 1999 | 6 | 0.170 |
Why?
|
| Uterus | 2 | 1990 | 77 | 0.170 |
Why?
|
| Liver Neoplasms, Experimental | 3 | 1990 | 38 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2019 | 2004 | 0.170 |
Why?
|
| Receptors, Opioid | 2 | 2016 | 60 | 0.170 |
Why?
|
| Colitis, Ulcerative | 1 | 2019 | 53 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2021 | 346 | 0.170 |
Why?
|
| Depression | 4 | 2011 | 942 | 0.170 |
Why?
|
| Delusions | 4 | 1990 | 20 | 0.170 |
Why?
|
| Trees | 2 | 1996 | 8 | 0.160 |
Why?
|
| Sensitivity and Specificity | 7 | 2014 | 1753 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 3 | 1994 | 186 | 0.160 |
Why?
|
| Students | 1 | 2020 | 233 | 0.160 |
Why?
|
| Wounds and Injuries | 2 | 2020 | 334 | 0.160 |
Why?
|
| Stress, Psychological | 2 | 2011 | 824 | 0.160 |
Why?
|
| Plant Stems | 3 | 2002 | 6 | 0.160 |
Why?
|
| Prognosis | 2 | 2017 | 2093 | 0.160 |
Why?
|
| Models, Neurological | 1 | 1999 | 136 | 0.160 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 1997 | 29 | 0.150 |
Why?
|
| Opioid-Related Disorders | 4 | 2012 | 298 | 0.150 |
Why?
|
| Genetic Association Studies | 3 | 2012 | 103 | 0.150 |
Why?
|
| Diazepam | 1 | 1997 | 23 | 0.150 |
Why?
|
| Carbolines | 1 | 1997 | 19 | 0.150 |
Why?
|
| Ribosome Inactivating Proteins, Type 2 | 4 | 2000 | 4 | 0.150 |
Why?
|
| Sensorimotor Cortex | 1 | 2017 | 18 | 0.150 |
Why?
|
| Personality | 1 | 1997 | 66 | 0.150 |
Why?
|
| Registries | 1 | 2020 | 730 | 0.150 |
Why?
|
| Aspirin | 7 | 1991 | 295 | 0.150 |
Why?
|
| Thromboxane B2 | 2 | 1990 | 108 | 0.150 |
Why?
|
| Visual Perception | 2 | 2017 | 124 | 0.150 |
Why?
|
| Parietal Lobe | 1 | 2017 | 59 | 0.150 |
Why?
|
| Arousal | 2 | 2014 | 168 | 0.150 |
Why?
|
| Affective Disorders, Psychotic | 2 | 1994 | 23 | 0.150 |
Why?
|
| Pregnancy | 15 | 2012 | 2331 | 0.150 |
Why?
|
| Liver Diseases | 2 | 2021 | 193 | 0.150 |
Why?
|
| Phosphatidic Acids | 1 | 2016 | 11 | 0.150 |
Why?
|
| Exploratory Behavior | 1 | 1997 | 79 | 0.150 |
Why?
|
| Connectome | 1 | 2018 | 91 | 0.150 |
Why?
|
| Gene-Environment Interaction | 2 | 2014 | 31 | 0.150 |
Why?
|
| Sleep | 2 | 2009 | 263 | 0.140 |
Why?
|
| Placebos | 4 | 2018 | 195 | 0.140 |
Why?
|
| Interleukins | 1 | 1996 | 79 | 0.140 |
Why?
|
| Disease | 2 | 1986 | 41 | 0.140 |
Why?
|
| Proof of Concept Study | 1 | 2016 | 38 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 614 | 0.140 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2018 | 413 | 0.140 |
Why?
|
| Alcohols | 1 | 2016 | 13 | 0.140 |
Why?
|
| Cold Temperature | 2 | 2006 | 90 | 0.140 |
Why?
|
| Behavior, Animal | 3 | 1997 | 470 | 0.140 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 55 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 290 | 0.140 |
Why?
|
| Marijuana Abuse | 4 | 2012 | 251 | 0.140 |
Why?
|
| Pilot Projects | 5 | 2020 | 1341 | 0.140 |
Why?
|
| Statistics as Topic | 3 | 2014 | 219 | 0.140 |
Why?
|
| Cognition Disorders | 1 | 1999 | 342 | 0.140 |
Why?
|
| Self Administration | 1 | 2017 | 419 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 6 | 1995 | 852 | 0.140 |
Why?
|
| Lithium | 3 | 1989 | 76 | 0.140 |
Why?
|
| Monocytes | 1 | 1996 | 210 | 0.140 |
Why?
|
| Cytotoxins | 2 | 1990 | 23 | 0.140 |
Why?
|
| Carbohydrate Sequence | 6 | 1996 | 45 | 0.140 |
Why?
|
| Seizures | 2 | 1996 | 279 | 0.140 |
Why?
|
| Mice | 23 | 2011 | 8472 | 0.140 |
Why?
|
| Indomethacin | 4 | 1989 | 107 | 0.130 |
Why?
|
| Molecular Sequence Data | 7 | 1996 | 1446 | 0.130 |
Why?
|
| Reference Values | 4 | 2016 | 579 | 0.130 |
Why?
|
| Liver | 3 | 2010 | 1118 | 0.130 |
Why?
|
| Oleanolic Acid | 2 | 1996 | 7 | 0.130 |
Why?
|
| Hospitalization | 7 | 2012 | 977 | 0.130 |
Why?
|
| Plant Roots | 1 | 1995 | 22 | 0.130 |
Why?
|
| Narcotics | 2 | 2008 | 65 | 0.130 |
Why?
|
| Hydrocortisone | 5 | 2006 | 291 | 0.130 |
Why?
|
| Thinking | 1 | 1995 | 30 | 0.130 |
Why?
|
| Calibration | 4 | 2017 | 73 | 0.130 |
Why?
|
| Fetus | 3 | 1991 | 157 | 0.130 |
Why?
|
| Chemistry, Clinical | 1 | 1994 | 6 | 0.120 |
Why?
|
| Disease Progression | 2 | 2015 | 1037 | 0.120 |
Why?
|
| Receptors, Serotonin | 2 | 2010 | 74 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2011 | 567 | 0.120 |
Why?
|
| Desipramine | 4 | 1993 | 47 | 0.120 |
Why?
|
| Age Factors | 7 | 2020 | 1860 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2000 | 1070 | 0.120 |
Why?
|
| Naloxone | 3 | 1996 | 56 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 320 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1996 | 626 | 0.120 |
Why?
|
| Patient Dropouts | 1 | 2014 | 98 | 0.120 |
Why?
|
| Benzylamines | 1 | 2013 | 28 | 0.120 |
Why?
|
| Endpoint Determination | 2 | 2018 | 82 | 0.120 |
Why?
|
| Data Collection | 2 | 2014 | 420 | 0.120 |
Why?
|
| Anxiety | 3 | 2016 | 422 | 0.120 |
Why?
|
| Niacinamide | 1 | 2013 | 31 | 0.120 |
Why?
|
| Quinoxalines | 1 | 2014 | 78 | 0.120 |
Why?
|
| Plant Leaves | 2 | 2004 | 49 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 492 | 0.120 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 2 | 1990 | 27 | 0.120 |
Why?
|
| Benzazepines | 1 | 2014 | 104 | 0.120 |
Why?
|
| Phenols | 2 | 1998 | 73 | 0.120 |
Why?
|
| Gestational Age | 2 | 2012 | 389 | 0.110 |
Why?
|
| Genetics, Population | 2 | 2012 | 21 | 0.110 |
Why?
|
| Prostaglandins | 3 | 1989 | 65 | 0.110 |
Why?
|
| Secondary Prevention | 2 | 2013 | 291 | 0.110 |
Why?
|
| Nicotinic Agonists | 1 | 2014 | 111 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 102 | 0.110 |
Why?
|
| Ribosome Inactivating Proteins | 3 | 2000 | 3 | 0.110 |
Why?
|
| Ricin | 1 | 1992 | 6 | 0.110 |
Why?
|
| Vesicular Transport Proteins | 1 | 2013 | 87 | 0.110 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1992 | 9 | 0.110 |
Why?
|
| Ribosomal Proteins | 1 | 1992 | 18 | 0.110 |
Why?
|
| Self Disclosure | 2 | 2005 | 55 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 938 | 0.110 |
Why?
|
| Agoraphobia | 2 | 1989 | 59 | 0.110 |
Why?
|
| Cytokines | 1 | 1997 | 866 | 0.110 |
Why?
|
| Panic | 2 | 1989 | 97 | 0.110 |
Why?
|
| RGS Proteins | 1 | 2012 | 22 | 0.110 |
Why?
|
| Neuregulin-1 | 1 | 2012 | 20 | 0.110 |
Why?
|
| Non-Fibrillar Collagens | 1 | 2012 | 9 | 0.110 |
Why?
|
| Basal Ganglia | 2 | 2012 | 45 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2014 | 285 | 0.110 |
Why?
|
| Colombia | 2 | 2001 | 8 | 0.110 |
Why?
|
| Genetic Linkage | 1 | 2012 | 90 | 0.110 |
Why?
|
| Coenzyme A Ligases | 1 | 2011 | 25 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 1992 | 87 | 0.100 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 2011 | 3 | 0.100 |
Why?
|
| Functional Neuroimaging | 1 | 2012 | 82 | 0.100 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2011 | 24 | 0.100 |
Why?
|
| Ibuprofen | 1 | 1991 | 30 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2019 | 880 | 0.100 |
Why?
|
| Maternal-Fetal Exchange | 2 | 1990 | 57 | 0.100 |
Why?
|
| Convulsants | 1 | 1991 | 4 | 0.100 |
Why?
|
| Exons | 1 | 2011 | 122 | 0.100 |
Why?
|
| Naphthyridines | 1 | 1991 | 20 | 0.100 |
Why?
|
| Phobic Disorders | 2 | 1989 | 227 | 0.100 |
Why?
|
| Sample Size | 2 | 2011 | 79 | 0.100 |
Why?
|
| Fear | 2 | 1989 | 239 | 0.100 |
Why?
|
| Amino Acid Substitution | 2 | 2008 | 137 | 0.100 |
Why?
|
| Clinical Chemistry Tests | 1 | 2010 | 2 | 0.100 |
Why?
|
| Glycosides | 2 | 1988 | 14 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 2005 | 2673 | 0.100 |
Why?
|
| Prolactin | 3 | 1990 | 61 | 0.100 |
Why?
|
| Nerve Growth Factor | 1 | 2011 | 54 | 0.100 |
Why?
|
| Picrotoxin | 1 | 1990 | 14 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2009 | 411 | 0.100 |
Why?
|
| Psychomotor Agitation | 1 | 2011 | 63 | 0.100 |
Why?
|
| Bilirubin | 1 | 2010 | 51 | 0.100 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 87 | 0.100 |
Why?
|
| Consensus | 1 | 2011 | 211 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2010 | 104 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2011 | 94 | 0.090 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2010 | 4 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2011 | 955 | 0.090 |
Why?
|
| Central Nervous System | 1 | 1991 | 107 | 0.090 |
Why?
|
| Adrenocorticotropic Hormone | 4 | 2006 | 106 | 0.090 |
Why?
|
| Laboratories | 1 | 2010 | 44 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 137 | 0.090 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2010 | 20 | 0.090 |
Why?
|
| Medical Records | 1 | 2010 | 121 | 0.090 |
Why?
|
| Sulfhydryl Compounds | 1 | 1990 | 73 | 0.090 |
Why?
|
| Fetal Death | 3 | 1991 | 49 | 0.090 |
Why?
|
| 3' Flanking Region | 1 | 2009 | 1 | 0.090 |
Why?
|
| Oxazepam | 1 | 1989 | 3 | 0.090 |
Why?
|
| Cell Line | 5 | 2006 | 1752 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2011 | 269 | 0.090 |
Why?
|
| Research Design | 4 | 2018 | 729 | 0.090 |
Why?
|
| Synaptic Transmission | 1 | 1991 | 236 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 131 | 0.090 |
Why?
|
| Mannosidases | 1 | 2009 | 4 | 0.090 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2009 | 3 | 0.090 |
Why?
|
| Thyroid Function Tests | 1 | 1989 | 21 | 0.090 |
Why?
|
| Receptors, Kainic Acid | 1 | 2009 | 24 | 0.090 |
Why?
|
| Affinity Labels | 1 | 1989 | 66 | 0.080 |
Why?
|
| Protein Subunits | 1 | 2009 | 99 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 10 | 1991 | 2790 | 0.080 |
Why?
|
| Suicide, Attempted | 1 | 2009 | 72 | 0.080 |
Why?
|
| Azides | 1 | 1989 | 56 | 0.080 |
Why?
|
| Social Control, Informal | 1 | 2008 | 8 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 237 | 0.080 |
Why?
|
| Parasitic Sensitivity Tests | 2 | 2006 | 8 | 0.080 |
Why?
|
| Child | 6 | 2011 | 6400 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 96 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2002 | 317 | 0.080 |
Why?
|
| Culture | 2 | 1986 | 75 | 0.080 |
Why?
|
| Ondansetron | 1 | 2008 | 13 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 1988 | 176 | 0.080 |
Why?
|
| Asparagine | 1 | 2008 | 15 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1046 | 0.080 |
Why?
|
| Genetic Carrier Screening | 1 | 2008 | 25 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 1989 | 130 | 0.080 |
Why?
|
| Psychomotor Performance | 2 | 2006 | 213 | 0.080 |
Why?
|
| Arbutin | 1 | 1987 | 1 | 0.080 |
Why?
|
| Structure-Activity Relationship | 4 | 1998 | 420 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2008 | 117 | 0.080 |
Why?
|
| Hydroquinones | 1 | 1987 | 15 | 0.080 |
Why?
|
| Chromatography, Ion Exchange | 2 | 2000 | 73 | 0.080 |
Why?
|
| Choice Behavior | 2 | 2005 | 85 | 0.080 |
Why?
|
| Mice, Inbred C3H | 7 | 1989 | 134 | 0.080 |
Why?
|
| Riboflavin | 1 | 2007 | 15 | 0.080 |
Why?
|
| Pimozide | 2 | 1985 | 3 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2003 | 597 | 0.070 |
Why?
|
| Trypanosomatina | 1 | 2006 | 1 | 0.070 |
Why?
|
| Clusiaceae | 1 | 2006 | 1 | 0.070 |
Why?
|
| Albizzia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Medicine, African Traditional | 1 | 2006 | 2 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 2 | 2005 | 201 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 1990 | 377 | 0.070 |
Why?
|
| Life Style | 1 | 2009 | 338 | 0.070 |
Why?
|
| Touch | 1 | 2006 | 25 | 0.070 |
Why?
|
| Neuropsychological Tests | 3 | 1999 | 517 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2007 | 107 | 0.070 |
Why?
|
| Neurocognitive Disorders | 1 | 1986 | 23 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 737 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2006 | 20 | 0.070 |
Why?
|
| Cultural Characteristics | 1 | 1986 | 42 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2013 | 2356 | 0.070 |
Why?
|
| Indoles | 1 | 1986 | 146 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2002 | 765 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2004 | 546 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 1988 | 154 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1293 | 0.070 |
Why?
|
| Parasitic Diseases | 1 | 1985 | 9 | 0.070 |
Why?
|
| Electrophoresis, Capillary | 2 | 2016 | 15 | 0.070 |
Why?
|
| Muscle Cells | 1 | 2005 | 30 | 0.070 |
Why?
|
| Dexamethasone | 3 | 1997 | 150 | 0.070 |
Why?
|
| Toxicity Tests | 1 | 2005 | 26 | 0.070 |
Why?
|
| Research | 3 | 2000 | 214 | 0.070 |
Why?
|
| Body Weight | 4 | 2013 | 554 | 0.070 |
Why?
|
| Plant Components, Aerial | 1 | 2004 | 2 | 0.070 |
Why?
|
| Chagas Disease | 1 | 2004 | 8 | 0.060 |
Why?
|
| Chromosome Mapping | 3 | 2013 | 188 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2008 | 866 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2006 | 215 | 0.060 |
Why?
|
| Random Allocation | 4 | 1991 | 442 | 0.060 |
Why?
|
| Social Support | 1 | 2007 | 423 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 497 | 0.060 |
Why?
|
| Psychometrics | 3 | 1996 | 514 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2010 | 7264 | 0.060 |
Why?
|
| Dysthymic Disorder | 1 | 2003 | 3 | 0.060 |
Why?
|
| Food Additives | 1 | 2003 | 4 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2012 | 137 | 0.060 |
Why?
|
| Drug Industry | 1 | 2004 | 54 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2006 | 275 | 0.060 |
Why?
|
| Accidents, Traffic | 2 | 2020 | 109 | 0.060 |
Why?
|
| Thromboxanes | 1 | 1983 | 53 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 1983 | 95 | 0.060 |
Why?
|
| Immunoassay | 2 | 2014 | 64 | 0.060 |
Why?
|
| Parasites | 1 | 1983 | 4 | 0.060 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2001 | 79 | 0.060 |
Why?
|
| Microwaves | 1 | 1983 | 31 | 0.060 |
Why?
|
| Community Health Services | 1 | 2004 | 141 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 81 | 0.060 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 1996 | 79 | 0.060 |
Why?
|
| Sleep Stages | 1 | 1983 | 30 | 0.060 |
Why?
|
| Receptors, Glutamate | 1 | 2003 | 22 | 0.060 |
Why?
|
| Polymers | 2 | 1998 | 244 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 2 | 2008 | 296 | 0.060 |
Why?
|
| Rural Population | 1 | 1986 | 397 | 0.060 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2003 | 34 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2004 | 714 | 0.060 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2002 | 4 | 0.050 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2002 | 8 | 0.050 |
Why?
|
| Contraceptive Agents | 1 | 1982 | 13 | 0.050 |
Why?
|
| India | 1 | 2002 | 41 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 28 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2006 | 150 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 2 | 2006 | 138 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 216 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2004 | 295 | 0.050 |
Why?
|
| Work Capacity Evaluation | 1 | 2002 | 8 | 0.050 |
Why?
|
| Plant Bark | 1 | 2001 | 1 | 0.050 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2001 | 25 | 0.050 |
Why?
|
| Environment | 1 | 2002 | 115 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 62 | 0.050 |
Why?
|
| Family Practice | 1 | 2004 | 312 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2001 | 85 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2005 | 310 | 0.050 |
Why?
|
| Cattle | 1 | 2002 | 475 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 1983 | 307 | 0.050 |
Why?
|
| Volatilization | 1 | 2001 | 13 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1139 | 0.050 |
Why?
|
| Outpatients | 1 | 2002 | 127 | 0.050 |
Why?
|
| Models, Statistical | 2 | 2016 | 446 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2003 | 331 | 0.050 |
Why?
|
| Taste | 1 | 2001 | 49 | 0.050 |
Why?
|
| Linoleic Acids | 1 | 1980 | 12 | 0.050 |
Why?
|
| Diet | 3 | 2003 | 513 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 370 | 0.050 |
Why?
|
| Tremor | 1 | 1980 | 16 | 0.050 |
Why?
|
| Pergolide | 1 | 2000 | 12 | 0.050 |
Why?
|
| Thalamus | 1 | 2001 | 82 | 0.050 |
Why?
|
| Family Therapy | 1 | 1981 | 82 | 0.050 |
Why?
|
| Demography | 3 | 2004 | 279 | 0.050 |
Why?
|
| Orosomucoid | 1 | 2000 | 5 | 0.050 |
Why?
|
| Galactose | 1 | 2000 | 16 | 0.050 |
Why?
|
| Haptoglobins | 1 | 2000 | 12 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2001 | 114 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2001 | 187 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2000 | 216 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 791 | 0.050 |
Why?
|
| Wounds, Gunshot | 1 | 2020 | 48 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 272 | 0.050 |
Why?
|
| Tea | 1 | 2000 | 23 | 0.050 |
Why?
|
| School Health Services | 1 | 2020 | 72 | 0.050 |
Why?
|
| Interview, Psychological | 2 | 2011 | 113 | 0.050 |
Why?
|
| ROC Curve | 1 | 2001 | 392 | 0.050 |
Why?
|
| Personality Tests | 2 | 1997 | 9 | 0.050 |
Why?
|
| Injury Severity Score | 1 | 2020 | 204 | 0.050 |
Why?
|
| Clinical Protocols | 3 | 1994 | 172 | 0.040 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1990 | 25 | 0.040 |
Why?
|
| Mental Disorders | 2 | 2011 | 659 | 0.040 |
Why?
|
| Schizophrenia | 2 | 2011 | 206 | 0.040 |
Why?
|
| Gene Expression | 2 | 2009 | 770 | 0.040 |
Why?
|
| Diphenylhexatriene | 1 | 1999 | 2 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2000 | 74 | 0.040 |
Why?
|
| Oils, Volatile | 1 | 1999 | 9 | 0.040 |
Why?
|
| Thyrotropin | 2 | 1990 | 49 | 0.040 |
Why?
|
| Chemical Phenomena | 3 | 1986 | 62 | 0.040 |
Why?
|
| Chemistry | 3 | 1986 | 45 | 0.040 |
Why?
|
| Diterpenes | 1 | 1979 | 42 | 0.040 |
Why?
|
| Colon | 1 | 2000 | 168 | 0.040 |
Why?
|
| Vasodilation | 1 | 1998 | 85 | 0.040 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 2 | 1995 | 7 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2000 | 308 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 1999 | 57 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2016 | 91 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 174 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2001 | 400 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 344 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.040 |
Why?
|
| Alcoholics Anonymous | 2 | 2011 | 13 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2006 | 1615 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 191 | 0.040 |
Why?
|
| Personality Development | 1 | 1997 | 11 | 0.040 |
Why?
|
| Isoelectric Focusing | 2 | 1995 | 42 | 0.040 |
Why?
|
| Social Dominance | 1 | 1997 | 4 | 0.040 |
Why?
|
| False Positive Reactions | 2 | 1995 | 95 | 0.040 |
Why?
|
| Plant Lectins | 1 | 1997 | 20 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 1997 | 31 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 1997 | 20 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 299 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2016 | 11 | 0.040 |
Why?
|
| Immunoblotting | 2 | 1995 | 254 | 0.040 |
Why?
|
| Ritanserin | 1 | 1996 | 5 | 0.040 |
Why?
|
| Avoidance Learning | 1 | 1997 | 58 | 0.040 |
Why?
|
| Serotonin Agents | 1 | 1996 | 13 | 0.040 |
Why?
|
| Menstrual Cycle | 1 | 1997 | 64 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 780 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1997 | 236 | 0.040 |
Why?
|
| Quality Control | 1 | 2016 | 81 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 1996 | 86 | 0.040 |
Why?
|
| Ovary | 1 | 1997 | 99 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 260 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2009 | 218 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 1998 | 382 | 0.040 |
Why?
|
| Bromocriptine | 1 | 1996 | 8 | 0.040 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1996 | 31 | 0.040 |
Why?
|
| Fluoxetine | 1 | 1996 | 40 | 0.030 |
Why?
|
| Antibodies | 1 | 1997 | 241 | 0.030 |
Why?
|
| Pain Threshold | 1 | 1996 | 55 | 0.030 |
Why?
|
| Bias | 1 | 1996 | 148 | 0.030 |
Why?
|
| Serotonin | 1 | 1996 | 144 | 0.030 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 1995 | 9 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2012 | 151 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1995 | 9 | 0.030 |
Why?
|
| Photic Stimulation | 2 | 2008 | 229 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1997 | 222 | 0.030 |
Why?
|
| Optical Rotation | 1 | 1995 | 1 | 0.030 |
Why?
|
| Models, Structural | 1 | 1995 | 22 | 0.030 |
Why?
|
| Carbohydrate Conformation | 1 | 1995 | 25 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1996 | 330 | 0.030 |
Why?
|
| Haiti | 2 | 1986 | 10 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2014 | 6 | 0.030 |
Why?
|
| Densitometry | 1 | 1994 | 15 | 0.030 |
Why?
|
| Patient Admission | 1 | 1995 | 99 | 0.030 |
Why?
|
| Necrosis | 1 | 1995 | 239 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1994 | 164 | 0.030 |
Why?
|
| Observer Variation | 1 | 1995 | 330 | 0.030 |
Why?
|
| Phenotype | 2 | 2010 | 946 | 0.030 |
Why?
|
| Aminopeptidases | 1 | 2013 | 6 | 0.030 |
Why?
|
| LIM Domain Proteins | 1 | 2013 | 15 | 0.030 |
Why?
|
| Lasers | 1 | 1994 | 61 | 0.030 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2013 | 11 | 0.030 |
Why?
|
| Cell Death | 1 | 1995 | 329 | 0.030 |
Why?
|
| 1-Naphthylamine | 1 | 1993 | 11 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1993 | 45 | 0.030 |
Why?
|
| Receptors, Dopamine | 2 | 1983 | 119 | 0.030 |
Why?
|
| Electroencephalography | 1 | 1996 | 418 | 0.030 |
Why?
|
| Pharmacognosy | 1 | 1993 | 2 | 0.030 |
Why?
|
| Mexico | 1 | 1993 | 38 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 113 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 84 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 38 | 0.030 |
Why?
|
| Trichosanthin | 1 | 1992 | 1 | 0.030 |
Why?
|
| Stereotyped Behavior | 3 | 1987 | 42 | 0.030 |
Why?
|
| Germany | 1 | 2012 | 67 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 13 | 0.030 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 1992 | 21 | 0.030 |
Why?
|
| Leukemia, T-Cell | 1 | 1992 | 21 | 0.030 |
Why?
|
| Alcoholic Beverages | 2 | 2004 | 18 | 0.030 |
Why?
|
| Pregnancy Complications | 2 | 2007 | 286 | 0.030 |
Why?
|
| Buspirone | 1 | 1992 | 36 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1992 | 122 | 0.030 |
Why?
|
| Autoantibodies | 1 | 1995 | 434 | 0.030 |
Why?
|
| CpG Islands | 1 | 2012 | 51 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 705 | 0.030 |
Why?
|
| Genome, Human | 1 | 2012 | 62 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1992 | 230 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 214 | 0.030 |
Why?
|
| Thyroxine | 2 | 1990 | 62 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2011 | 9 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 54 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2012 | 52 | 0.030 |
Why?
|
| Nicotinic Antagonists | 1 | 2011 | 11 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 349 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 208 | 0.030 |
Why?
|
| Selection Bias | 1 | 2011 | 23 | 0.030 |
Why?
|
| Menopause | 1 | 2011 | 47 | 0.030 |
Why?
|
| Azetidines | 1 | 2011 | 6 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2013 | 210 | 0.030 |
Why?
|
| Cell Division | 1 | 1992 | 541 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1991 | 111 | 0.030 |
Why?
|
| Periplaneta | 1 | 1991 | 2 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 536 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2011 | 119 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 160 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2011 | 45 | 0.020 |
Why?
|
| Methylation | 1 | 1991 | 56 | 0.020 |
Why?
|
| Acetaldehyde | 1 | 1990 | 18 | 0.020 |
Why?
|
| Hydrolysis | 1 | 1991 | 144 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1990 | 89 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Prostaglandins F | 2 | 1987 | 13 | 0.020 |
Why?
|
| Counseling | 1 | 2012 | 279 | 0.020 |
Why?
|
| Fetal Growth Retardation | 1 | 1990 | 56 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1992 | 1082 | 0.020 |
Why?
|
| Isomerism | 1 | 1990 | 63 | 0.020 |
Why?
|
| Nutritive Value | 1 | 1990 | 22 | 0.020 |
Why?
|
| Dinoprost | 2 | 1987 | 27 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 532 | 0.020 |
Why?
|
| Mitochondria | 1 | 1995 | 643 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 1990 | 169 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1990 | 260 | 0.020 |
Why?
|
| Axons | 1 | 1991 | 139 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1990 | 358 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2000 | 306 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 83 | 0.020 |
Why?
|
| Action Potentials | 1 | 1991 | 223 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 424 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1027 | 0.020 |
Why?
|
| Rabbits | 2 | 1987 | 509 | 0.020 |
Why?
|
| Family Relations | 1 | 2009 | 47 | 0.020 |
Why?
|
| Domestic Violence | 1 | 2009 | 36 | 0.020 |
Why?
|
| Triiodothyronine | 1 | 1989 | 22 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Pyridines | 1 | 2011 | 261 | 0.020 |
Why?
|
| Population | 1 | 2009 | 11 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 521 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1329 | 0.020 |
Why?
|
| Psychological Tests | 1 | 1989 | 96 | 0.020 |
Why?
|
| Teratogens | 1 | 1988 | 11 | 0.020 |
Why?
|
| Synapses | 1 | 1991 | 222 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2009 | 161 | 0.020 |
Why?
|
| Psychoses, Alcoholic | 1 | 1988 | 5 | 0.020 |
Why?
|
| Rats, Wistar | 2 | 2000 | 371 | 0.020 |
Why?
|
| France | 1 | 1988 | 26 | 0.020 |
Why?
|
| Hypothermia | 1 | 1988 | 37 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 1989 | 206 | 0.020 |
Why?
|
| Legislation, Drug | 1 | 1988 | 9 | 0.020 |
Why?
|
| Pharmacology | 1 | 1988 | 9 | 0.020 |
Why?
|
| Tannins | 1 | 1988 | 17 | 0.020 |
Why?
|
| Employment | 1 | 2009 | 154 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1663 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 281 | 0.020 |
Why?
|
| Prostaglandins D | 1 | 1987 | 2 | 0.020 |
Why?
|
| Prostaglandin D2 | 1 | 1987 | 21 | 0.020 |
Why?
|
| Vanuatu | 1 | 1986 | 1 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 1987 | 86 | 0.020 |
Why?
|
| Embryonic and Fetal Development | 1 | 1987 | 74 | 0.020 |
Why?
|
| Bignoniaceae | 1 | 2006 | 1 | 0.020 |
Why?
|
| Cerebral Cortex | 2 | 1988 | 415 | 0.020 |
Why?
|
| Cameroon | 1 | 2006 | 5 | 0.020 |
Why?
|
| Apocynaceae | 1 | 2006 | 2 | 0.020 |
Why?
|
| Receptors, Prostaglandin | 1 | 1987 | 74 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2006 | 73 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 1987 | 97 | 0.020 |
Why?
|
| Family | 1 | 2009 | 293 | 0.020 |
Why?
|
| Kinetics | 2 | 1985 | 1047 | 0.020 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2006 | 20 | 0.020 |
Why?
|
| Immersion | 1 | 2006 | 10 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2006 | 29 | 0.020 |
Why?
|
| Cats | 1 | 1987 | 292 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 2006 | 46 | 0.020 |
Why?
|
| Creatinine | 1 | 1987 | 243 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2006 | 108 | 0.020 |
Why?
|
| Dinoprostone | 1 | 1987 | 110 | 0.020 |
Why?
|
| Oxygen | 1 | 2008 | 386 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2006 | 78 | 0.020 |
Why?
|
| Drinking | 1 | 1986 | 35 | 0.020 |
Why?
|
| Ovariectomy | 1 | 1985 | 49 | 0.020 |
Why?
|
| Hypochondriasis | 1 | 1985 | 3 | 0.020 |
Why?
|
| Absorption | 1 | 1985 | 49 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1992 | 3185 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 193 | 0.020 |
Why?
|
| Europe | 1 | 2005 | 195 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 1984 | 17 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1988 | 659 | 0.020 |
Why?
|
| Genomics | 1 | 2005 | 167 | 0.020 |
Why?
|
| Food Industry | 1 | 2003 | 7 | 0.020 |
Why?
|
| Internationality | 1 | 2004 | 74 | 0.020 |
Why?
|
| Rest | 1 | 2004 | 78 | 0.010 |
Why?
|
| Decision Trees | 1 | 2003 | 74 | 0.010 |
Why?
|
| Beverages | 1 | 2004 | 50 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1983 | 149 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 2004 | 100 | 0.010 |
Why?
|
| Pruritus | 1 | 1983 | 35 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1983 | 282 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 246 | 0.010 |
Why?
|
| Magic | 1 | 1982 | 2 | 0.010 |
Why?
|
| Embryo Implantation | 1 | 1982 | 17 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 2688 | 0.010 |
Why?
|
| Oxytocics | 1 | 1982 | 14 | 0.010 |
Why?
|
| Hormones | 1 | 1982 | 42 | 0.010 |
Why?
|
| Aggression | 1 | 2003 | 98 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1982 | 133 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1983 | 532 | 0.010 |
Why?
|
| Imagination | 1 | 2001 | 38 | 0.010 |
Why?
|
| Purkinje Cells | 1 | 1980 | 18 | 0.010 |
Why?
|
| Aging | 1 | 1987 | 911 | 0.010 |
Why?
|
| Propranolol | 1 | 1980 | 102 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2006 | 702 | 0.010 |
Why?
|
| Azoxymethane | 1 | 2000 | 28 | 0.010 |
Why?
|
| Mice, Inbred Strains | 2 | 1991 | 181 | 0.010 |
Why?
|
| Carcinogens | 1 | 2000 | 86 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 73 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1982 | 586 | 0.010 |
Why?
|
| Chamomile | 1 | 1999 | 1 | 0.010 |
Why?
|
| Herb-Drug Interactions | 1 | 1999 | 5 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 447 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 160 | 0.010 |
Why?
|
| Wine | 1 | 1998 | 4 | 0.010 |
Why?
|
| Dimerization | 1 | 1999 | 99 | 0.010 |
Why?
|
| Clone Cells | 1 | 1979 | 67 | 0.010 |
Why?
|
| Forensic Medicine | 1 | 1999 | 26 | 0.010 |
Why?
|
| Anisotropy | 1 | 1999 | 105 | 0.010 |
Why?
|
| Phospholipids | 1 | 1999 | 108 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1999 | 112 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2000 | 219 | 0.010 |
Why?
|
| Limbic System | 1 | 1999 | 106 | 0.010 |
Why?
|
| Polyphenols | 1 | 1998 | 34 | 0.010 |
Why?
|
| Liposomes | 1 | 1999 | 107 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1999 | 125 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 241 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1999 | 523 | 0.010 |
Why?
|
| Diazepam Binding Inhibitor | 1 | 1996 | 2 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1998 | 211 | 0.010 |
Why?
|
| Headache | 1 | 1996 | 68 | 0.010 |
Why?
|
| Morocco | 1 | 1996 | 1 | 0.010 |
Why?
|
| Aurintricarboxylic Acid | 1 | 1995 | 1 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 1995 | 28 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 351 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1995 | 69 | 0.010 |
Why?
|
| Imipramine | 1 | 1993 | 44 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 2550 | 0.010 |
Why?
|
| Acute Disease | 1 | 1995 | 658 | 0.010 |
Why?
|
| Glutathione | 1 | 1995 | 343 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1992 | 74 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 1992 | 147 | 0.010 |
Why?
|
| Aftercare | 1 | 1992 | 114 | 0.010 |
Why?
|
| Rhinitis | 1 | 1996 | 383 | 0.010 |
Why?
|
| Schizophrenia, Paranoid | 1 | 1990 | 8 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 1990 | 53 | 0.010 |
Why?
|
| Monoamine Oxidase | 1 | 1989 | 26 | 0.010 |
Why?
|
| Lithium Carbonate | 1 | 1989 | 31 | 0.010 |
Why?
|
| Prostaglandin Antagonists | 1 | 1989 | 11 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1989 | 284 | 0.010 |
Why?
|
| Body Temperature | 1 | 1988 | 116 | 0.000 |
Why?
|
| Apoptosis | 1 | 1995 | 1640 | 0.000 |
Why?
|
| Litter Size | 1 | 1987 | 14 | 0.000 |
Why?
|
| Psychotic Disorders | 1 | 1989 | 157 | 0.000 |
Why?
|
| Fertility | 1 | 1987 | 60 | 0.000 |
Why?
|
| Temperature | 1 | 1988 | 340 | 0.000 |
Why?
|
| Cricetinae | 1 | 1987 | 262 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1987 | 379 | 0.000 |
Why?
|
| Reflex | 1 | 1985 | 21 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1985 | 120 | 0.000 |
Why?
|
| Species Specificity | 1 | 1985 | 302 | 0.000 |
Why?
|
| Motor Activity | 1 | 1985 | 621 | 0.000 |
Why?
|
| Aortic Valve Stenosis | 1 | 1982 | 177 | 0.000 |
Why?
|